Patents by Inventor Maureen Fitch-Bruhns
Maureen Fitch-Bruhns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190209704Abstract: The present disclosure provides novel linker-cytotoxin conjugates and antibody-drug conjugates, including homogenous antibody-drug conjugates, comprising the novel linker-cytotoxin conjugates.Type: ApplicationFiled: October 19, 2015Publication date: July 11, 2019Inventors: David Y. JACKSON, Edward HA, Paul SAUER, Simeon BOWERS, Maureen Fitch Bruhns, Jorge Monteon, Christopher Behrens, Randall L. Halcomb
-
Publication number: 20170198031Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: ApplicationFiled: October 20, 2016Publication date: July 13, 2017Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. GURNEY, Timothy Charles HOEY, Edward Thein Htun van der HORST, Aaron Ken SATO, Yuan Ching LIU, Maureen Fitch BRUHNS, John A. LEWICKI
-
Publication number: 20170183405Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: ApplicationFiled: October 12, 2016Publication date: June 29, 2017Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. GURNEY, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Patent number: 9617340Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.Type: GrantFiled: November 21, 2014Date of Patent: April 11, 2017Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Aaron Ken Sato, Maureen Fitch-Bruhns
-
Patent number: 9505832Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: January 20, 2015Date of Patent: November 29, 2016Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
-
Patent number: 9499613Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: December 19, 2014Date of Patent: November 22, 2016Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Patent number: 9132189Abstract: The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia.Type: GrantFiled: March 12, 2013Date of Patent: September 15, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Edward Thein Htun van der Horst, Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Publication number: 20150197563Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: ApplicationFiled: January 20, 2015Publication date: July 16, 2015Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
-
Publication number: 20150183878Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.Type: ApplicationFiled: November 21, 2014Publication date: July 2, 2015Inventors: Austin GURNEY, Aaron Ken Sato, Maureen Fitch-Bruhns
-
Publication number: 20150166963Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: ApplicationFiled: December 19, 2014Publication date: June 18, 2015Applicant: OncoMed Pharmaceuticals, IncInventors: Austin L. GURNEY, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Patent number: 8980260Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: March 14, 2013Date of Patent: March 17, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
-
Patent number: 8945547Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: March 14, 2013Date of Patent: February 3, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Patent number: 8945874Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: March 13, 2013Date of Patent: February 3, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Patent number: 8945873Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: March 1, 2013Date of Patent: February 3, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
-
Patent number: 8921106Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.Type: GrantFiled: May 9, 2013Date of Patent: December 30, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Aaron Ken Sato, Maureen Fitch-Bruhns
-
Patent number: 8802103Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.Type: GrantFiled: May 15, 2008Date of Patent: August 12, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Timothy Hoey, Sanjeev Satyal, Maureen Fitch Bruhns
-
Publication number: 20140011271Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: ApplicationFiled: March 13, 2013Publication date: January 9, 2014Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Publication number: 20130323257Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.Type: ApplicationFiled: May 9, 2013Publication date: December 5, 2013Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. GURNEY, Aaron Ken Sato, Maureen Fitch-Bruhns
-
Publication number: 20130296536Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
-
Publication number: 20130280277Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: ApplicationFiled: March 14, 2013Publication date: October 24, 2013Inventors: Austin L. GURNEY, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod